Defective Fosamax Lead to Femur Fracture ~ OPOLAW Injury Blog

Tuesday, July 31, 2012

Defective Fosamax Lead to Femur Fracture

A defective product lawsuit has been filed against Merck Sharp & Dohme Corp. and Merck & Co., alleging that Fosamax caused a femur fracture in one woman. According to the complaint, the Plaintiff experienced a right subtrochanteric femur fracture in June 2010 after taking Fosamax consistently as prescribed for years. The lawsuit says that the fracture is a direct result of long-term treatment with the drug. In addition to having her thighbone broken, the suit alleges that the Plaintiff has suffered a number of serious consequences from taking Fosamax, including severe mental and physical pain and suffering, permanent injuries, emotional distress, economic loss due to medical expenses and living related expenses due to a new lifestyle. If the Defendants would have properly disclosed the risks related to using the drug over an extended period of time, the Plaintiff would not have taken Fosamax and endured the subsequent complications. The U.S. Food and Drug Administration (FDA) updated the label on Fosamax and other bisphosphonate drugs, such as Actonel and Boniva, in October 2010. A study published in May compared patients with different types of femur fractures, and found that 82 percent of patients with atypical femur fractures had taken bisphosphonates.

No comments:

Post a Comment